Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;10(5):623-46.
doi: 10.2217/rme.15.25.

Developing stem cell therapies for juvenile and adult-onset Huntington's disease

Kyle D Fink  1 , Peter Deng  1 , Audrey Torrest  1 , Heather Stewart  1 , Kari Pollock  1 , William Gruenloh  1 , Geralyn Annett  1 , Teresa Tempkin  2 , Vicki Wheelock  3 , Jan A Nolta  1
Affiliations
Review

Developing stem cell therapies for juvenile and adult-onset Huntington's disease

Kyle D Fink et al. Regen Med. 2015.

Abstract

Stem cell therapies have been explored as a new avenue for the treatment of neurologic disease and damage within the CNS in part due to their native ability to mimic repair mechanisms in the brain. Mesenchymal stem cells have been of particular clinical interest due to their ability to release beneficial neurotrophic factors and their ability to foster a neuroprotective microenviroment. While early stem cell transplantation therapies have been fraught with technical and political concerns as well as limited clinical benefits, mesenchymal stem cell therapies have been shown to be clinically beneficial and derivable from nonembryonic, adult sources. The focus of this review will be on emerging and extant stem cell therapies for juvenile and adult-onset Huntington's disease.

Keywords: Huntington's disease; regenerative medicine; stem cell; transplantation.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

    1. Dutta S, Singh G, Sreejith S et al. Cell therapy: the final frontier for treatment of neurological diseases. CNS Neurosci. Ther 19(1), 5–11 (2013). - PMC - PubMed
    1. Barker RA. Stem cells and neurodegenerative diseases: where is it all going? Regen. Med 7(6 Suppl), 26–31 (2012). - PubMed
    1. Karussis D, Petrou P, Kassis I. Clinical experience with stem cells and other cell therapies in neurological diseases. J. Neurol. Sci 324(1–2), 1–9 (2013). - PubMed
    1. Bachoud-Lévi A-C, Gaura V, Brugières P et al. Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 5(4), 303–309 (2006). - PubMed
    1. Cicchetti F, Saporta S, Hauser RA et al. Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration. Proc. Natl Acad. Sci. USA 106(30), 12483–12488 (2009). - PMC - PubMed

Substances